News & Views
Telix welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen…
Read more
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252…
Read moreTelix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual…
Read more
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian…
Read more
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for…
Read more
News,
Telix announces a global clinical supply agreement with Eckert & Ziegler for…
Read more
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its…
Read more
Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer….
Read more
Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot…
Read more
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic…
Read more